Patents by Inventor Glenn R. Pilkington
Glenn R. Pilkington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8221759Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: September 30, 2011Date of Patent: July 17, 2012Assignee: Intracel Resources LLCInventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, Jr., Brian R. Murphy
-
Publication number: 20120087909Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: September 30, 2011Publication date: April 12, 2012Inventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, JR., Brian R. Murphy
-
Publication number: 20090311247Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule such as EPO, Flt3-Ligand, Flt3, PDGF-B or VEGF-165 or chimeric molecules thereof comprising at least a portion of the protein molecule, wherein the protein or chimeric molecule has a profile of measurable physiochemical parameters which is indicative of, associated with or forms the basis of, one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: November 18, 2005Publication date: December 17, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Teresa A. Domagala, Raina J. Simpson, Glenn R. Pilkington, Catherine A. Liddell, Ingrid Boehm, Carol M. Y. Lee
-
Publication number: 20090232808Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the tumour necrosis factor (TNF) superfamily such as TNF-a, Lymphotoxin-a (LT-a), TNFRI, TNFRII, OX40, BAFF, NGFR, Fas Ligand or chimeric molecules thereof comprising at least a portion of the protein molecule, such as TNF-a-Fc, LT-a-Fc, TNFRI-Fc, TNFRII-Fc, OX40-Fc, BAFF-Fc, NGFR-Fc, Fas Ligand-Fc; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: January 27, 2006Publication date: September 17, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Teresa A. Domagala, Glenn R. Pilkington, Ingrid Boehm, Carol M. Y. Lee, Mei Ann Lim, Nikolien S. Thomas
-
Publication number: 20090202472Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the IL-2 protein family such as IL-2, IL-2Ra, IL-2Rb, IL-2Rg or chimeric molecules thereof, such as IL-2-Fc, IL-2Ra-Fc, IL-2Rb-Fc and IL2Rg-Fc, comprising at least a portion of the protein molecule; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: November 24, 2005Publication date: August 13, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Glenn R. Pilkington, Catherine A. Liddell
-
Publication number: 20090175819Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule that comprises a dimeric 4-helix bundle, such as IFN-a2B, IFN-b1, IFN-g, IL-10 or its receptor, such as IFNAR2, IL-10Ra or chimeric molecules thereof comprising at least a portion of the protein molecule, such as IFN-a2B-Fc, IFN-b1-Fc, IFN-g-Fc, IFNAR2-Fc, IL-IO-Fc, IL-10Ra-Fc; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: February 14, 2006Publication date: July 9, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Teresa A. Domagala, Carol M. Y. Lee, Raina J. Simpson, Ingrid Boehm, Stuart Jackson, Catherine A. Liddell, Glenn R. Pilkington, Melissa Corbett
-
Publication number: 20090142294Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the short chain 4 helix bundle superfamily such as GM-CSF, IL-3, IL-4 and IL-5 or chimeric molecules thereof comprising at least a portion of the protein molecule, such as GM-CSF-Fc, IL-3-Fc, IL-4-Fc and IL-5-Fc; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: January 25, 2006Publication date: June 4, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Glenn R. Pilkington, Catherine A. Liddell, Ingrid Boehm
-
Publication number: 20090136444Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the IL-6 protein family such as G-CSF, IL-11, IL-6, LIF or chimeric molecules thereof, comprising at least a portion of the protein molecule; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: November 11, 2005Publication date: May 28, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Stuart Jackson, Teresa A. Domagala, Raina J. Simpson, Glenn R. Pilkington, Catherine A. Liddell
-
Publication number: 20090110684Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: April 24, 2008Publication date: April 30, 2009Inventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, JR., Brian R. Murphy
-
Patent number: 7488477Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: April 30, 2003Date of Patent: February 10, 2009Assignee: Intracel Resources LLCInventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, Jr., Brian R. Murphy
-
Publication number: 20040005324Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: April 30, 2003Publication date: January 8, 2004Inventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, Brian R. Murphy